459 related articles for article (PubMed ID: 26642063)
1. Global strategies for cervical cancer prevention.
Pimple S; Mishra G; Shastri S
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):4-10. PubMed ID: 26642063
[TBL] [Abstract][Full Text] [Related]
2. The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
Monk BJ; Herzog TJ
Am J Obstet Gynecol; 2007 Oct; 197(4):337-9. PubMed ID: 17904955
[No Abstract] [Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer screening in high- and low-resource countries: implications and new developments.
Hoppenot C; Stampler K; Dunton C
Obstet Gynecol Surv; 2012 Oct; 67(10):658-67. PubMed ID: 23112073
[TBL] [Abstract][Full Text] [Related]
5. Global strategies for cervical cancer prevention and screening.
Pimple SA; Mishra GA
Minerva Ginecol; 2019 Aug; 71(4):313-320. PubMed ID: 30808155
[TBL] [Abstract][Full Text] [Related]
6. (At Least) Once in Her Lifetime: Global Cervical Cancer Prevention.
Castle PE; Pierz A
Obstet Gynecol Clin North Am; 2019 Mar; 46(1):107-123. PubMed ID: 30683258
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
[TBL] [Abstract][Full Text] [Related]
12. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer screening and prevention in low-resource settings.
Bradford L; Goodman A
Clin Obstet Gynecol; 2013 Mar; 56(1):76-87. PubMed ID: 23337844
[TBL] [Abstract][Full Text] [Related]
15. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
[TBL] [Abstract][Full Text] [Related]
17. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
[TBL] [Abstract][Full Text] [Related]
18. The next steps in cervical screening.
Sankaranarayanan R; Qiao YL; Keita N
Womens Health (Lond); 2015 Mar; 11(2):201-12. PubMed ID: 25776294
[TBL] [Abstract][Full Text] [Related]
19. Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.
Fokom-Domgue J; Combescure C; Fokom-Defo V; Tebeu PM; Vassilakos P; Kengne AP; Petignat P
BMJ; 2015 Jul; 351():h3084. PubMed ID: 26142020
[TBL] [Abstract][Full Text] [Related]
20. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
